newsfilter
← Latest News
GlobeNewswire·

Spero Therapeutics Announces Second Quarter 2026 Operating Results and Provides Business Update

SPRO
  • Spero Therapeutics entered an exclusive license agreement with Innovent Biologics for SP001, a Phase 2-ready third-generation anti-CD40L antibody, gaining worldwide rights excluding Greater China.
  • The U.S. FDA approved Utebzi (tebipenem pivoxil) as the first oral carbapenem antibiotic for complicated urinary tract infections in adults, with commercialization rights held by GSK.
  • Spero secured $105 million in non-recourse, non-dilutive financing backed by future Utebzi royalties, extending its cash runway into the second half of 2029.
  • Debra Zack, M.D., Ph.D., was appointed as Chief Medical Officer to oversee clinical development strategy for immune-mediated diseases.
  • The company reported a net loss of $9.6 million for the second quarter of 2026, compared to a $1.7 million loss in the same period in 2025.
  • Research and development expenses decreased to $3.4 million in the second quarter of 2026 from $10.7 million in 2025 due to reduced clinical activities related to the stopped Utebzi Phase 3 trial.
  • No revenue was recognized in the second quarter of 2026 as prior deferred revenue related to collaboration agreements was fully recognized in previous periods.
  • Cash reserves as of June 30, 2026, stood at $50.8 million, excluding the proceeds from the July 2026 financing transaction.
  • Spero plans to advance SP001 into a Phase 2 study for IgG4-related disease while evaluating additional development opportunities in immune-mediated diseases.